Cargando…

Differential effects of norUDCA and UDCA in obstructive cholestasis in mice

BACKGROUND & AIMS: The quest for effective drugs to treat cholangiopathies led to the development of norUDCA previously shown to have potent choleretic effects and to heal cholangiopathy in Abcb4 knockout (Abcb4(−/−)) mice. Its mother compound UDCA had detrimental effects in common bile duct lig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fickert, Peter, Pollheimer, Marion J., Silbert, Dagmar, Moustafa, Tarek, Halilbasic, Emina, Krones, Elisabeth, Durchschein, Franziska, Thüringer, Andrea, Zollner, Gernot, Denk, Helmut, Trauner, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3650580/ https://www.ncbi.nlm.nih.gov/pubmed/23369794 http://dx.doi.org/10.1016/j.jhep.2013.01.026

Ejemplares similares

NorUDCA promotes degradation of α1-antitrypsin mutant Z protein by inducing autophagy through AMPK/ULK1 pathway
por: Tang, Youcai, et al.
Publicado: (2018)

Evidence for functional selectivity in TUDC- and norUDCA-induced signal transduction via α(5)β(1) integrin towards choleresis
por: Bonus, Michele, et al.
Publicado: (2020)

Glyceric Prodrug of Ursodeoxycholic Acid (UDCA): Novozym 435-Catalyzed Synthesis of UDCA-Monoglyceride
por: Zappaterra, Federico, et al.
Publicado: (2021)

UDCA in UC: A true disease modifier or symptoms reliever?
por: Sulais, Eman Al
Publicado: (2021)

Perinatal exposure to UDCA prevents neonatal cholestasis in Cyp2c70(-/-) mice with human-like bile acids
por: de Vries, Hilde D., et al.
Publicado: (2022)

Latest development in the synthesis of ursodeoxycholic acid (UDCA): a critical review
por: Tonin, Fabio, et al.
Publicado: (2018)

Repurposing UDCA, an FXR Inhibitor, to Prevent SARS-Cov-2 Infection
por: Prayitno, Khairunnadiya, et al.
Publicado: (2023)

UDCA, a novel strategy for preventing SARS-CoV-2 infection via FXR-mediated ACE2 downregulation: UDCA and SARS-CoV-2 infection
por: Chen, Mengjiao, et al.
Publicado: (2023)

Waking Action of Ursodeoxycholic Acid (UDCA) Involves Histamine and GABA(A) Receptor Block
por: Yanovsky, Yevgenij, et al.
Publicado: (2012)

Pathogenesis of primary sclerosing cholangitis
por: Pollheimer, Marion J., et al.
Publicado: (2011)

Pretreatment with Ursodeoxycholic Acid (UDCA) as a Novel Pharmacological Intervention in Hepatobiliary Scintigraphy
por: Jeong, Hwan-Jeong, et al.
Publicado: (2005)

External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis
por: Gazda, Jakub, et al.
Publicado: (2021)

Gut Microbial Profile Changes in Patients with Gallbladder Stones after UDCA/CDCA Treatment
por: Lee, Jungnam, et al.
Publicado: (2023)

Ursodeoxycholic Acid (UDCA) Exerts Anti-Atherogenic Effects by Inhibiting RAGE Signaling in Diabetic Atherosclerosis
por: Chung, Jihwa, et al.
Publicado: (2016)

NCX 1000 Alone or in Combination with Vitamin E Reverses Experimental Nonalcoholic Steatohepatitis in the Rat Similarly to UDCA
por: Haddad, Yara, et al.
Publicado: (2011)

A network meta-analysis of the efficacy and side effects of udca-based therapies for primary sclerosing cholangitis
por: Zhu, Gui-Qi, et al.
Publicado: (2015)

Preclinical Evaluation of UDCA-Containing Oral Formulation in Mice for the Treatment of Wet Age-Related Macular Degeneration
por: Maharjan, Pooja, et al.
Publicado: (2019)

The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort study
por: Jones, David E.J., et al.
Publicado: (2022)

Network Meta-Analysis of Randomized Controlled Trials: Efficacy and Safety of UDCA-Based Therapies in Primary Biliary Cirrhosis
por: Zhu, Gui-Qi, et al.
Publicado: (2015)

Bivalent Ligand UDCA-LPE Inhibits Pro-Fibrogenic Integrin Signalling by Inducing Lipid Raft-Mediated Internalization
por: Su, Jie, et al.
Publicado: (2018)

Ursodeoxycholic Acid (UDCA) Exerts Anti-Atherogenic Effects by Inhibiting Endoplasmic Reticulum (ER) Stress Induced by Disturbed Flow
por: Chung, Jihwa, et al.
Publicado: (2015)

A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis
por: Ma, Hong, et al.
Publicado: (2016)

Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a model of NASH
por: Marchianò, Silvia, et al.
Publicado: (2023)

Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis
por: Zhang, Yan, et al.
Publicado: (2015)

UDCA Inhibits Hypoxic Hepatocellular Carcinoma Cell–Induced Angiogenesis Through Suppressing HIF-1α/VEGF/IL-8 Intercellular Signaling
por: Lin, Wanfu, et al.
Publicado: (2021)

Hypercortisolism in patients with cholestasis is associated with disease severity
por: Theiler-Schwetz, Verena, et al.
Publicado: (2021)

U12, a UDCA Derivative, Acts as an Anti-Hepatoma Drug Lead and Inhibits the mTOR/S6K1 and Cyclin/CDK Complex Pathways
por: Xu, Yang, et al.
Publicado: (2014)

The Bile Acid-Phospholipid Conjugate Ursodeoxycholyl-Lysophosphatidylethanolamide (UDCA-LPE) Disintegrates the Lipid Backbone of Raft Plasma Membrane Domains by the Removal of the Membrane Phospholipase A2
por: Stremmel, Wolfgang, et al.
Publicado: (2019)

Changes in the Intestinal Microbiome during a Multispecies Probiotic Intervention in Compensated Cirrhosis
por: Horvath, Angela, et al.
Publicado: (2020)

The chronic kidney disease epidemiology collaboration equation combining creatinine and cystatin C accurately assesses renal function in patients with cirrhosis
por: Krones, Elisabeth, et al.
Publicado: (2015)

Primary sclerosing cholangitis – The arteriosclerosis of the bile duct?
por: Fickert, Peter, et al.
Publicado: (2007)

Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases
por: Halilbasic, Emina, et al.
Publicado: (2013)

Bile acid transporters and regulatory nuclear receptors in the liver and beyond
por: Halilbasic, Emina, et al.
Publicado: (2013)

Cystic Fibrosis Related Liver Disease—Another Black Box in Hepatology
por: Staufer, Katharina, et al.
Publicado: (2014)

Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2(−/−) mice by modulating composition, signalling and excretion of faecal bile acids
por: Fuchs, Claudia Daniela, et al.
Publicado: (2018)

Recent advances in understanding and managing cholestasis
por: Wagner, Martin, et al.
Publicado: (2016)

Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID‐19 in patients with chronic liver disease
por: Hartl, Lukas, et al.
Publicado: (2022)

Randomised clinical trial: the effects of a multispecies probiotic vs. placebo on innate immune function, bacterial translocation and gut permeability in patients with cirrhosis
por: Horvath, A., et al.
Publicado: (2016)

Molecular alterations of canalicular transport systems in experimental models of cholestasis: possible functional correlations.
por: Trauner, M.
Publicado: (1997)

In Vivo (1)H MR Spectroscopy of Biliary Components of Human Gallbladder at 7T
por: Gajdošík, Martin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fngbvdi2qcq37pbnifprjf7mt8